Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Monopar Therapeutics Inc MNPR

Healthcare Biotechnology
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The Company is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The Company has several compounds in development, which include MNPR-101-Zr... see more

Recent & Breaking News (NDAQ:MNPR)

Monopar to Present at the 34th Annual Roth Conference and Maxim's 2022 Virtual Growth Conference

GlobeNewswire March 8, 2022

Monopar Announces Clinical and Preclinical Program Updates

GlobeNewswire February 15, 2022

Monopar to Present at the H.C. Wainwright BioConnect Conference

GlobeNewswire January 7, 2022

Monopar Advances Dosing of Camsirubicin to Higher Level Than Tested In Any Previous Clinical Trial

GlobeNewswire December 8, 2021

Monopar Therapeutics Reports Third Quarter 2021 Financial Results and Recent Clinical Developments

GlobeNewswire November 12, 2021

Monopar Announces First Patient Dosed in Phase 1b Trial Evaluating Camsirubicin for the Treatment of Advanced Soft Tissue Sarcoma

GlobeNewswire October 27, 2021

Monopar Initiates Open-Label Phase 1b Clinical Trial Evaluating Camsirubicin in Patients with Advanced Soft Tissue Sarcoma

GlobeNewswire September 16, 2021

Monopar Expands Phase 2b/3 VOICE Clinical Trial to Europe

GlobeNewswire September 13, 2021

Monopar Therapeutics to Present at Upcoming Investor Conferences in September

GlobeNewswire September 9, 2021

Monopar Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Updates

GlobeNewswire August 12, 2021

Monopar Reaches Target Number of Clinical Sites in Phase 2b Portion of 2b/3 Validive® VOICE Trial

GlobeNewswire August 5, 2021

Monopar Announces FDA Clearance to Proceed with Camsirubicin Clinical Trial Targeting Advanced Soft Tissue Sarcoma

GlobeNewswire August 3, 2021

Monopar Appoints Octávio Costa, MD, as Chief Medical Officer

GlobeNewswire July 12, 2021

Monopar to Present Results from Analysis of Oropharyngeal Cancer Patients in Completed Phase 2 Validive® Trial at MASCC/ISOO

GlobeNewswire June 24, 2021

Monopar Announces New Drug Candidate, MNPR-202, and Enters into Collaboration Agreement with the National University of Singapore for Preclinical Evaluation in Cancer

GlobeNewswire June 3, 2021

Monopar Therapeutics Expands Leadership Team with Appointment of Andrew Cittadine as Chief Operating Officer

GlobeNewswire June 1, 2021

Monopar and NorthStar Announce Filing of Composition of Matter Patent Protecting MNPR-101 Radiotherapeutic

GlobeNewswire May 26, 2021

Monopar and NorthStar Announce Patent Filing on Promising Radiopharmaceutical Discovery

GlobeNewswire May 24, 2021

Monopar Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Updates

GlobeNewswire May 13, 2021

Monopar's uPA Antibody Fragment Radiotracer Shows Potential for PET Imaging of Breast Cancer in Preclinical Study

GlobeNewswire March 30, 2021